United States  

Gilead's remdesivir gets conditional EU clearance

Video Credit: Reuters Studio - Duration: 00:59s - Published
Gilead's remdesivir gets conditional EU clearance

Gilead's remdesivir gets conditional EU clearance

The European Commission said Friday it had given conditional approval for the use of antiviral drug remdesivir in severe COVID-19 patients.

As Fred Katayama reports, that makes it the region's first authorized therapy to treat the virus.

0
shares
ShareTweetSavePostSend
 

πŸ’‘ One News Page Knowledge: Other News Mentions

European Commission European Commission Executive branch of the European Union

EU insists European companies could replace Huawei in 5G network [Video]

EU insists European companies could replace Huawei in 5G network

Nokia and Ericsson can replace Huawei if the Chinese tech giant were to be sidelined for security reasons, the European Commission said on Friday.View on euronews

Credit: euronews (in English)    Duration: 01:25Published
Full steam ahead: hydrogen train boosted by EU climate goals [Video]

Full steam ahead: hydrogen train boosted by EU climate goals

As the European Commission pushes for cleaner fuels to fight global warming, hydrogen could mean the end of the line for diesel-powered locomotives.View on euronews

Credit: euronews (in English)    Duration: 01:49Published
'Impasse' EU talks extended to Sunday [Video]

'Impasse' EU talks extended to Sunday

European Union leaders ended a second day of negotiations late on Saturday without a concrete plan to pump hundreds of billions of euros into their economies ravaged by coronavirus and would resume on Sunday. Conway G. Gittens has the details.

Credit: Reuters - Politics    Duration: 01:10Published
Coronavirus: no ''mini-Schengens", warns EU Commission VP [Video]

Coronavirus: no ''mini-Schengens", warns EU Commission VP

European Commission Vice President Margaritis Schinas talks to the Global Conversation about the future of Europe's border-free travel Schengen zone and what European solidarity should look like once Europe comes out of the coronavirus crisis.View on euronews

Credit: euronews (in English)    Duration: 08:13Published
EU plans tax overhaul to shore up post-lockdown economy [Video]

EU plans tax overhaul to shore up post-lockdown economy

It came as Brussels suffered a setback when a court rejected a European Commission demand that Apple should pay €13 billion in Irish back taxes.View on euronews

Credit: euronews (in English)    Duration: 01:53Published

Gilead Sciences American pharmaceutical company

Drugmaker Says Remdesivir Can Lower COVID-19 Death Risk By 62% [Video]

Drugmaker Says Remdesivir Can Lower COVID-19 Death Risk By 62%

The antiviral drug Remdesivir has proven to be effective in the treatment of COVID-19. According to UPI, the drug can lower the risk of death in COVID-19 patients by 62%. U.S. drugmaker Gilead Sciences reported the new data on Friday. Gilead said the results came from a comparative analysis among 312 patients in its Phase 3 clinical trial. There have been over 3.4 million confirmed cases of coronavirus in the U.S., with a death toll of 138,247 people.

Credit: Wochit News    Duration: 00:32Published
Gilead sparks Wall Street rally [Video]

Gilead sparks Wall Street rally

U.S. stocks rose Friday as a positive analysis on Gilead Sciences Inc's antiviral drug to treat COVID-19 helped to soothe investor worries over a record rise in coronavirus cases in the United States. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:20Published
Gilead says remdesivir cuts death risk [Video]

Gilead says remdesivir cuts death risk

Gilead Sciences said Friday additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill COVID-19 patients. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:04Published
Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment [Video]

Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment

Gilead is the pharmaceutical company behind a drug that’s been approved for COVID emergencies. The FDA officially announced the medicine could be used in treating COVID-19 patients. Gilead has now announced the drug will cost $3,120 per typical treatment course for insured individuals. Research has indicated the drug could cut the recovery time for hospitalized COVID-19 patients. It could shorten satsy by several days, reports Gizmodo.

Credit: Wochit News    Duration: 00:35Published

European Union European Union Economic and political union of European states

Brexit briefing: 150 days until the end of the transition period [Video]

Brexit briefing: 150 days until the end of the transition period

The UK left the European Union on January 31. Here we look at the latestfigures and key dates in the ongoing Brexit process.

Credit: PA - Press Association STUDIO    Duration: 00:50Published
Brexit briefing: 151 days until the end of the transition period [Video]

Brexit briefing: 151 days until the end of the transition period

The UK left the European Union on January 31. Here we look at the latestfigures and key dates in the ongoing Brexit process.

Credit: PA - Press Association STUDIO    Duration: 00:50Published
Brexit briefing: 152 days until the end of the transition period [Video]

Brexit briefing: 152 days until the end of the transition period

The UK left the European Union on January 31. Here we look at the latestfigures and key dates in the ongoing Brexit process.

Credit: PA - Press Association STUDIO    Duration: 00:50Published
[CDATA[Coronavirus: EU says it struck deal with Sanofi for 300 million doses of potential COVID-19 vaccine]] [Video]

[CDATA[Coronavirus: EU says it struck deal with Sanofi for 300 million doses of potential COVID-19 vaccine]]

[CDATA[]]

Credit: Euronews English    Duration: 01:00Published
Coronavirus: EU says it struck deal with Sanofi for 300 million doses of potential COVID-19 vaccine [Video]

Coronavirus: EU says it struck deal with Sanofi for 300 million doses of potential COVID-19 vaccine

Coronavirus: EU says it struck deal with Sanofi for 300 million doses of potential COVID-19 vaccineView on euronews

Credit: euronews (in English)    Duration: 01:00Published

Fred Katayama journalist

Nasdaq surges on megacap earnings [Video]

Nasdaq surges on megacap earnings

The Nasdaq jumped more than 1% on Friday, powered by strong earnings from some of the largest U.S. companies, but the Dow and S&P finished with smaller gains as uncertainty about the government's next round of coronavirus aid kept economic worries on the radar. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:27Published
Don't chase gold, silver rally: strategist [Video]

Don't chase gold, silver rally: strategist

Susquehanna Investment Group's Chris Murphy says more and more people are chasing the huge rally in gold and silver. He tells Reuters' Fred Katayama there are better options for hedging inflation.

Credit: Reuters Studio    Duration: 04:13Published
Fed will reassure markets - economist [Video]

Fed will reassure markets - economist

Spartan Capital Securities' Peter Cardillo expects the Fed to say it'll do "whatever it takes" to keep adding liquidity to the markets when policymakers meet this week. But he also tells Reuters' Fred Katayama that he thinks there's a good chance the markets will pull back, regardless of the Fed, because "the economy is faltering."

Credit: Reuters Studio    Duration: 04:14Published
Hasbro revenue plunges despite strong demand [Video]

Hasbro revenue plunges despite strong demand

Hasbro reported a sharp drop in revenue Monday, as production shutdowns due to the COVID-19 pandemic crimped the toymaker's efforts to cash in on strong demand for its board games. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:08Published
Market correction is likely: strategist [Video]

Market correction is likely: strategist

Invesco's Brian Levitt says the equities market will likely face a correction or volatility in the near term. But he also tells Reuters' Fred Katayama a new market cycle has emerged where stocks will benefit from improved economic activity and low rates over the longer term.

Credit: Reuters Studio    Duration: 04:47Published

You Might Like


Tweets about this

EzzelarabLaila

laila ezzelarab RT @ColorMeRed: Gilead gets Hong Kong conditional approval for remdesivir to treat Covid-19 https://t.co/9n48lkpqwE via @PharmaTechFocus 1 week ago

ColorMeRed

Color Me Red πŸ©ΈπŸ‡ΊπŸ‡Έ Gilead gets Hong Kong conditional approval for remdesivir for Covid-19 https://t.co/9n48lkpqwE via @PharmaTechFocus 1 week ago